Ruling in Risperdal case does not affect Taiwan users: official

Taiwan's Department of Health said Thursday that local patients using the drug Risperdal would not be affected by a ruling in the United States that fined Johnson & Johnson and a subsidiary, the drug's manufacturer, for improperly marketing the drug and downplaying its potential health risks.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)